Your browser doesn't support javascript.
loading
18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial.
Manoharan, Prakash; Salem, Ahmed; Mistry, Hitesh; Gornall, Michael; Harden, Susan; Julyan, Peter; Locke, Imogen; McAleese, Jonathan; McMenemin, Rhona; Mohammed, Nazia; Snee, Michael; Woods, Sarah; Westwood, Thomas; Faivre-Finn, Corinne.
Afiliação
  • Manoharan P; Department of Radiology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Department of Nuclear Medicine, The Christie National Health Service Foundation Trust, Manchester, United Kingdom. Electronic address: prakash.manoharan@christie.nhs.uk.
  • Salem A; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Mistry H; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Division of Pharmacy, University of Manchester, Manchester, United Kingdom.
  • Gornall M; Department of Nuclear Medicine, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Harden S; Department of Clinical Oncology, Addenbrooke's Hospital, Cambridge, United Kingdom.
  • Julyan P; Department of Nuclear Medicine, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Locke I; Department of Clinical Oncology, The Royal Marsden National Health Service Foundation Trust, Surrey, United Kingdom.
  • McAleese J; Department of Clinical Oncology, Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, United Kingdom.
  • McMenemin R; Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle-upon-Tyne, United Kingdom.
  • Mohammed N; Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
  • Snee M; Department of Clinical Oncology, Leeds Cancer Centre, St James's Hospital, Leeds, United Kingdom.
  • Woods S; Department of Nuclear Medicine, Manchester University National Health Service Foundation Trust, Manchester, United Kingdom.
  • Westwood T; Department of Radiology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom; Department of Nuclear Medicine, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
  • Faivre-Finn C; Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom; Department of Clinical Oncology, The Christie National Health Service Foundation Trust, Manchester, United Kingdom.
J Thorac Oncol ; 14(7): 1296-1305, 2019 07.
Article em En | MEDLINE | ID: mdl-31002954
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Fluordesoxiglucose F18 / Carcinoma de Pequenas Células do Pulmão / Quimiorradioterapia / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Fluordesoxiglucose F18 / Carcinoma de Pequenas Células do Pulmão / Quimiorradioterapia / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Neoplasias Pulmonares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article